Mechano-redox control of integrin de-adhesion
- University of New South Wales, Australia
- University of Sydney, Australia
- Tel Aviv University, Israel
- Heidelberg Institute of Theoretical Studies, Germany
- University of Los Andes, Colombia
Abstract
How proteins harness mechanical force to control function is a significant biological question. Here we describe a human cell surface receptor that couples ligand binding and force to trigger a chemical event which controls the adhesive properties of the receptor. Our studies of the secreted platelet oxidoreductase, ERp5, have revealed that it mediates release of fibrinogen from activated platelet αIIbβ3 integrin. Protein chemical studies show that ligand binding to extended αIIbβ3 integrin renders the βI-domain Cys177-Cys184 disulfide bond cleavable by ERp5. Fluid shear and force spectroscopy assays indicate that disulfide cleavage is enhanced by mechanical force. Cell adhesion assays and molecular dynamics simulations demonstrate that cleavage of the disulfide induces long-range allosteric effects within the βI-domain, mainly affecting the metal-binding sites, that results in release of fibrinogen. This coupling of ligand binding, force and redox events to control cell adhesion may be employed to regulate other protein-protein interactions.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
Article and author information
Author details
Camilo Aponte-Santamaría
Funding
National Health and Medical Research Council (Research Fellowship 1110219)
- Philip J Hogg
Deutsche Forschungsgemeinschaft (Research Unit FOR 1543)
- Katra Kolšek
- Camilo Aponte-Santamaría
- Frauke Gräter
National Heart Foundation of Australia (Australia Postdoctoral Fellowship 101285)
- Lining Ju
Klaus Tschira Stiftung
- Frauke Gräter
Diabetes Australia Research Trust (Grant G179720)
- Lining Ju
Royal College of Pathologists of Australasia (Kanematsu/Novo Nordisk Research Award)
- Freda Passam
- Lining Ju
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: All procedures involving collection of human blood from healthy volunteers were in accordance with the St George Hospital Human Ethics Committee (HREC 12/252), Human Research Ethics Committee (HREC) (Project number 2014/244) of the University of Sydney , and the Helsinki Declaration of 1983.
Copyright
© 2018, Passam et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,442
- views
-
- 473
- downloads
-
- 53
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Mechano-redox control of integrin de-adhesion
eLife 7:e34843.
https://doi.org/10.7554/eLife.34843
Further reading
-
- Biochemistry and Chemical Biology
- Structural Biology and Molecular Biophysics
Nature has inspired the design of improved inhibitors for cancer-causing proteins.
-
- Biochemistry and Chemical Biology
Mutations in the kinase and juxtamembrane domains of the MET Receptor Tyrosine Kinase are responsible for oncogenesis in various cancers and can drive resistance to MET-directed treatments. Determining the most effective inhibitor for each mutational profile is a major challenge for MET-driven cancer treatment in precision medicine. Here, we used a deep mutational scan (DMS) of ~5764 MET kinase domain variants to profile the growth of each mutation against a panel of 11 inhibitors that are reported to target the MET kinase domain. We validate previously identified resistance mutations, pinpoint common resistance sites across type I, type II, and type I ½ inhibitors, unveil unique resistance and sensitizing mutations for each inhibitor, and verify non-cross-resistant sensitivities for type I and type II inhibitor pairs. We augment a protein language model with biophysical and chemical features to improve the predictive performance for inhibitor-treated datasets. Together, our study demonstrates a pooled experimental pipeline for identifying resistance mutations, provides a reference dictionary for mutations that are sensitized to specific therapies, and offers insights for future drug development.
